Bradykinin decreases podocyte permeability through ADAM17-dependent epidermal growth factor receptor activation and zonula occludens-1 rearrangement

Journal of Pharmacology and Experimental Therapeutics

Volumn 334, Issue 3, 2010, Pages 775-783

  Dey, Mamon ^a   Baldys, Aleksander ^a   Sumter, Dezmond B ^a   Göoz, Pal ^a   Luttrell, Louis M ^a,b   Raymond, John R ^a,b   Göoz, Monika ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; BRADYKININ; BRADYKININ B2 RECEPTOR; DISINTEGRIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIREGULIN; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN ZO1; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME; MEMBRANE PROTEIN; PHOSPHOPROTEIN; TJP1 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR-ALPHA CONVERTASE;

ANIMAL CELL; ARTICLE; CELL PERMEABILIZATION; CONTROLLED STUDY; DOWN REGULATION; GENE SILENCING; MOUSE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; AGONISTS; ANIMAL; CELL MEMBRANE PERMEABILITY; DRUG EFFECTS; GENETICS; GLOMERULUS; METABOLISM; PHYSIOLOGY; RNA INTERFERENCE; WESTERN BLOTTING;

ADAM PROTEINS; ANIMALS; BLOTTING, WESTERN; BRADYKININ; CELL MEMBRANE PERMEABILITY; KIDNEY GLOMERULUS; MEMBRANE PROTEINS; MICE; PHOSPHOPROTEINS; PODOCYTES; RECEPTOR CROSS-TALK; RECEPTOR, BRADYKININ B2; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, G-PROTEIN-COUPLED; RNA INTERFERENCE; SIGNAL TRANSDUCTION; ZONULA OCCLUDENS-1 PROTEIN;

EID: 77956246169     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.168054     Document Type: Article

References (40)

1. Ardaillou N, Blaise V, Costenbader K, Vassitch Y, and Ardaillou R (1996) Characterization of a B2-bradykinin receptor in human glomerular podocytes. Am J Physiol Renal Physiol 271:F754-F761.
2. Baldys A, Göoz M, Morinelli TA, Lee MH, Raymond JR Jr, Luttrell LM, and Raymond JR Sr (2009) Essential role of c-Cbl in amphiregulin-induced recycling and signaling of the endogenous epidermal growth factor receptor. Biochemistry 48:1462-1473.
3. Banan A, Fields JZ, Talmage DA, Zhang L, and Keshavarzian A (2002) PKC-ζ is required in EGF protection of microtubules and intestinal barrier integrity against oxidant injury. Am J Physiol Gastrointest Liver Physiol 282:G794-G808.
4. Benigni A, Tomasoni S, Gagliardini E, Zoja C, Grunkemeyer JA, Kalluri R, and Remuzzi G (2001) Blocking angiotensin II synthesis/activity preserves glomerular nephrin in rats with severe nephrosis. J Am Soc Nephrol 12:941-948.
5. Chen MC, Goliger J, Bunnett N, and Soll AH (2001) Apical and basolateral EGF receptors regulate gastric mucosal paracellular permeability. Am J Physiol Gastrointest Liver Physiol 280:G264-G272.
6. Doggrell SA (2006) Bradykinin B2 receptors as a target in diabetic nephropathy. Curr Opin Investig Drugs 7:251-255.
7. Forsyth CB, Banan A, Farhadi A, Fields JZ, Tang Y, Shaikh M, Zhang LJ, Engen PA, and Keshavarzian A (2007) Regulation of oxidant-induced intestinal permeability by metalloprotease-dependent epidermal growth factor receptor signaling. J Pharmacol Exp Ther 321:84-97.
8. Georgieva GS, Kurata S, Ikeda S, Eishi Y, Mitaka C, and Imai T (2007) Nonischemic lung injury by mediators from unilateral ischemic reperfused lung: ameliorating effect of tumor necrosis factor-α-converting enzyme inhibitor. Shock 27:84-90.
9. Göoz M, Göoz P, Luttrell LM, and Raymond JR (2006) 5-HT2A receptor induces ERK phosphorylation and proliferation through ADAM-17 tumor necrosis factor-α-converting enzyme (TACE) activation and heparin-bound epidermal growth factor-like growth factor (HB-EGF) shedding in mesangial cells. J Biol Chem 281:21004-21012.
10. Gross ML, El-Shakmak A, Szábó A, Koch A, Kuhlmann A, Münter K, Ritz E, and Amann K (2003) ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 46:856-868.
11. Izumi Y, Xu L, di Tomaso E, Fukumura D, and Jain RK (2002) Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 416:279-280.
12. Jackson LF, Qiu TH, Sunnarborg SW, Chang A, Zhang C, Patterson C, and Lee DC (2003) Defective valvulogenesis in HB-EGF and TACE-null mice is associated with aberrant BMP signaling. EMBO J 22:2704-2716.
13. Kakoki M, Takahashi N, Jennette JC, and Smithies O (2004) Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci USA 101:13302-13305.
14. Kim HS, Kim MS, Hancock AL, Harper JC, Park JY, Poy G, Perantoni AO, Cam M, Malik K, and Lee SB (2007) Identification of novel Wilms' tumor suppressor gene target genes implicated in kidney development. J Biol Chem 282:16278-16287.
15. Lai XX, Ding GH, Huang CX, Shi M, and Chen C (2004) Angiotensin II-induced podocyte apoptosis: role of the MAPK subtypes. Beijing Da Xue Xue Bao 36:131-134.
16. Langham RG, Kelly DJ, Cox AJ, Gow RM, Holthofer H, and Gilbert RE (2004) Angiotensin II-induced proteinuria and expression of the podocyte slit pore membrane protein, nephrin. Nephrol Dial Transplant 19:262-263.
17. Langham RG, Kelly DJ, Cox AJ, Thomson NM, Holthöfer H, Zaoui P, Pinel N, Cordonnier DJ, and Gilbert RE (2002) Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 45:1572-1576.
18. Lautrette A, Li S, Alili R, Sunnarborg SW, Burtin M, Lee DC, Friedlander G, and Terzi F (2005) Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med 11:867-874.
19. Macconi D, Abbate M, Morigi M, Angioletti S, Mister M, Buelli S, Bonomelli M, Mundel P, Endlich K, Remuzzi A, et al. (2006) Permselective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. Am J Pathol 168:1073-1085.
20. Macconi D, Ghilardi M, Bonassi ME, Mohamed EI, Abbate M, Colombi F, Remuzzi G, and Remuzzi A (2000) Effect of angiotensin-converting enzyme inhibition on glomerular basement membrane permeability and distribution of zonula occludens- 1 in MWF rats. J Am Soc Nephrol 11:477-489.
21. Maltais I, Bachvarova M, Maheux P, Perron P, Marceau F, and Bachvarov D (2002) Bradykinin B2 receptor gene polymorphism is associated with altered urinary albumin/ creatinine values in diabetic patients. Can J Physiol Pharmacol 80:323-327.
22. Mifsud SA, Allen TJ, Bertram JF, Hulthen UL, Kelly DJ, Cooper ME, Wilkinson-Berka JL, and Gilbert RE (2001) Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Diabetologia 44:878-882.
23. Mishra R, Leahy P, and Simonson MS (2002) Gene expression profiling reveals role for EGF-family ligands in mesangial cell proliferation. Am J Physiol Renal Physiol 283:F1151-F1159.
24. Mukhin YV, Gooz M, Raymond JR, and Garnovskaya MN (2006) Collagenase-2 and -3 mediate epidermal growth factor receptor transactivation by bradykinin B2 receptor in kidney cells. J Pharmacol Exp Ther 318:1033-1043.
25. Mundel P, Reiser J, Zúñiga Mejía Borja A, Pavenstädt H, Davidson GR, Kriz W, and Zeller R (1997) Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 236:248-258.
26. Nabokov A, Amann K, Gassmann P, Schwarz U, Orth SR, and Ritz E (1998) The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity. Nephrol Dial Transplant 13:173-176.
27. Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, and Koide H (2000) Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 15:1379-1383.
28. Pavenstädt H (2000) Roles of the podocyte in glomerular function. Am J Physiol Renal Physiol 278:F173-F179.
29. Pawluczyk IZ, Patel SR, and Harris KP (2004) The role of bradykinin in the antifibrotic actions of perindoprilat on human mesangial cells. Kidney Int 65:1240-1251.
30. Prodromidi EI, Poulsom R, Jeffery R, Roufosse CA, Pollard PJ, Pusey CD, and Cook HT (2006) Bone marrow-derived cells contribute to podocyte regeneration and amelioration of renal disease in a mouse model of Alport syndrome. Stem Cells 24:2448-2455.
31. Ruiz-Ortega M, Rupérez M, Esteban V, Rodríguez-Vita J, Sánchez-López E, Carvajal G, and Egido J (2006) Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 21:16-20.
32. Seccia TM, Belloni AS, Guidolin D, Sticchi D, Nussdorfer GG, Pessina AC, and Rossi GP (2006) The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension. J Hypertens 24:1419-1427.
33. Shigematsu S, Ishida S, Gute DC, and Korthuis RJ (2002) Bradykinin-induced proinflammatory signaling mechanisms. Am J Physiol Heart Circ Physiol 283: H2676-H2686.
34. Singh AB, Sugimoto K, Dhawan P, and Harris RC (2007) Juxtacrine activation of EGFR regulates claudin expression and increases transepithelial resistance. Am J Physiol Cell Physiol 293:C1660-C1668.
35. Souza DG, Ferreira FL, Fagundes CT, Amaral FA, Vieira AT, Lisboa RA, Andrade MV, Trifilieff A, and Teixeira MM (2007) Effects of PKF242-484 and PKF241-466, novel dual inhibitors of TNF-α converting enzyme and matrix metalloproteinases, in a model of intestinal reperfusion injury in mice. Eur J Pharmacol 571: 72-80.
36. Thuringer D, Maulon L, and Frelin C (2002) Rapid transactivation of the vascular endothelial growth factor receptor KDR/Flk-1 by the bradykinin B2 receptor contributes to endothelial nitric-oxide synthase activation in cardiac capillary endothelial cells. J Biol Chem 277:2028-2032.
37. Wu W, Onn A, Isobe T, Itasaka S, Langley RR, Shitani T, Shibuya K, Komaki R, Ryan AJ, Fidler IJ, et al. (2007) Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 6:471-483.
38. Yokota K, Kishida M, Ogura T, Suzuki J, Otsuka F, Mimura Y, Takeda M, Nakamura Y, and Makino H (2003) Role of bradykinin in renoprotective effects by angiotensin II type 1 receptor antagonist in salt-sensitive hypertension. Hypertens Res 26:265-272.
39. Zhuang S, Yan Y, Daubert RA, and Schnellmann RG (2007) Epiregulin promotes proliferation and migration of renal proximal tubular cells. Am J Physiol Renal Physiol 293:F219-F226.
40. Zychma MJ, Gumprecht J, Zukowska-Szczechowska E, and Grzeszczak W (1999) Polymorphisms in the genes encoding for human kinin receptors and the risk of end-stage renal failure: results of transmission/disequilibrium test. The End-Stage Renal Disease Study Group. J Am Soc Nephrol 10:2120-2124.